{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:37Z","timestamp":1793600857068,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.diabres.2026.113206","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:11:34Z","timestamp":1772899894000},"page":"113206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence"],"prefix":"10.1016","volume":"235","author":[{"given":"Chun-Chi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-4707","authenticated-orcid":false,"given":"Ya-Yun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Che","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-2144","authenticated-orcid":false,"given":"Wei-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113206_b0005","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2026.113206_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0015","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113206_b0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/met.2015.1502","article-title":"A perspective on metabolic syndrome and nonalcoholic fatty liver disease","volume":"13","author":"Targher","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.diabres.2026.113206_b0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0035","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0040","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112918","article-title":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","volume":"229","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113206_b0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113206_b0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0065","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2026.113206_b0070","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113206_b0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2026.113206_b0090","article-title":"The cardiohepatic axis in metabolic disease: liver to heart","volume":"10","author":"Hakeem","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabres.2026.113206_b0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113206_b0100","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4254\/wjh.v10.i11.790","article-title":"Treating nonalcoholic steatohepatitis with antidiabetic drugs: will GLP-1 agonists end the struggle?","volume":"10","author":"Kalogirou","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0110","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2026.113206_b0115","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113206_b0120","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabres.2026.113206_b0125","article-title":"Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database","author":"Wu","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0130","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabres.2026.113206_b0135","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113206_b0140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1198\/000313001317097960","article-title":"On judging the significance of differences by examining the overlap between confidence intervals","volume":"55","author":"Schenker","year":"2001","journal-title":"Am Stat"},{"key":"10.1016\/j.diabres.2026.113206_b0145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2026.113206_b0150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice","volume":"8","author":"Bohne","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabres.2026.113206_b0155","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113206_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-024-02181-7","article-title":"Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance","volume":"23","author":"Cersosimo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113206_b0165","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0170","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0175","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0180","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): outcomes by sex","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2026.113206_b0185","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.diabres.2026.113206_b0190","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2021.05.012","article-title":"Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: data from the EMPA-REG OUTCOME trial","volume":"27","author":"Savarese","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabres.2026.113206_b0195","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.123.066915","article-title":"Expanding the definition of worsening heart failure and recognizing the importance of outpatient escalation of oral diuretics","volume":"148","author":"Greene","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113206_b0200","article-title":"SGLT2 inhibitors and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease: a real-world retrospective cohort study","author":"Pham","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2026.113206_b0205","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/apt.18502","article-title":"Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabres.2026.113206_b0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.49856","article-title":"Outcomes of SGLT-2i and GLP-1RA therapy among patients with type 2 diabetes and varying NAFLD status","volume":"6","author":"Bea","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2026.113206_b0215","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.diabres.2026.113206_b0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-023-01506-1","article-title":"Potential new therapeutic implications of semaglutide: new colours of the rainbow?","volume":"15","author":"Gouveri","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113206_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/oby.70065","article-title":"Semaglutide versus dulaglutide and liraglutide in Chinese patients with T2DM: a multicenter real-world study","volume":"34","author":"Xie","year":"2026","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2026.113206_b0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.diabres.2026.113206_b0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113206_b0240","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113206_b0245","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2026.113206_b0250","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2026.113206_b0255","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:39:45Z","timestamp":1793597985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"alternative-id":["S0168822726001257"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113206","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113206"}}